Novo Nordisk has committed to making all Wegovy dose strengths available in the US by the end of 2022, despite Australian type 2 diabetes patients being forced to go without for the next few months
NAD+ isnt suitable for those under 18 years old, with allergies to NAD+ or sterile solutions, or with any of the following health conditions
Other medications that affect gastric motility (opioids, anticholinergics, prokinetics) should also be held per protocol
Common side effects include nausea and vomiting (slightly more common with the pill version), diarrhoea and/or constipation and abdominal discomfort, but these generally settle once people get used to the medicine
Additionally, some patients underestimate portion sizes or caloric intake, unconsciously negating the appetite-suppressing benefits of their medication
Jardiance (empagliflozin) is an SGLT2 inhibitor, not a GLP-1 receptor agonist like Ozempic (semaglutide)